News

Caretaker Medical Awarded the Grand Prize in NIH RADx Tech for Maternal Health Challenge

Caretaker Medical, a digital health company focused on developing hemodynamic monitoring devices, today announced that it has been awarded the $525,000 grand prize in the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Technology for Maternal Health Challenge. The award recognizes Caretaker’s wireless, wearable wrist device, VitalStream, that can be used to monitor postpartum women for episodes of hyper- or hypotension, as well as detect the early onset of hemorrhage and sepsis. VitalStream continuously measures heart rate, blood pressure, respiration, cardiac output and stroke volume, among other vital signs.

In the US, over 80% of pregnancy-related deaths are preventable. And in 2020, 36% of deaths occurred 1-42 days postpartum. Continuous monitoring can help clinicians detect clinical decompensation sooner. A noninvasive, wireless monitor can expand advanced monitoring capabilities to more women and can potentially even be worn after hospital discharge.

“We are honored to receive this award and to be recognized for VitalStream’s potential to impact maternal health outcomes,” stated Jeff Pompeo, President and CEO of Caretaker Medical. “VitalStream can offer clinicians the continuous data they need to intervene earlier, potentially save the lives of new mothers.”

The RADx challenge prioritized technologies that are innovative, easy to use and can be used to help reduce health disparities.

For more information or to schedule a demonstration, contact Caretaker Medical.

Read more here.

Recent News

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …

10/20/2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights …